# Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis

> **NCT05451615** · PHASE3 · UNKNOWN · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Abatacept
- Treatment Compliance
- Rheumatoid Arthritis

## Interventions

- **DRUG:** Janus Kinase Inhibitor
- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT05451615
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-30
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451615, "Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05451615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*